Biocept, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products and clinical research.
Cytokeratin negative (CK?) CTCs are a phenotype of cells that has been under-appreciated because most current CTC capture and detection platforms utilize technology that is not able to recognize these cells. This publication describes the application of Biocept’s proprietary Cell Enrichment and Extraction (CEETM) platform for the capture of these CK? cells, as well as CK+ CTC phenotypes, in patient samples and animal models.
Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support. The company was founded on May 12, 1997 and is headquartered in San Diego, CA. [Source: MarketWatch]